Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2. Issue 6 (10th June 2021)

• Record Type: Journal Article
• Authors: Pellizzari, Giulia; Martinez, Olivier; Crescioli, Silvia; Page, Robert; Di Meo, Ashley; Mele, Silvia; Chiaruttini, Giulia; Hoinka, Jan; Batruch, Ihor; Prassas, Ioannis; Grandits, Melanie; López-Abente, Jacobo; Bugallo-Blanco, Eva; Ward, Malcolm; Bax, Heather J; French, Elise; Cheung, Anthony; Lombardi, Sara; Figini, Mariangela; Lacy, Katie E; Diamandis, Eleftherios P; Josephs, Debra H; Spicer, James; Papa, Sophie; Karagiannis, Sophia N
• Is Part Of: Journal for immunotherapy of cancer. Volume 9:Issue 6(2021)
• Publication Date: 2021-06-10
• Subjects: immunotherapy -- receptors -- chimeric antigen -- cytokines -- antibody specificity -- immunoassay; Cancer -- Immunotherapy -- Periodicals; Cancer -- Immunological aspects -- Periodicals; Tumors -- Immunological aspects -- Periodicals; Immunotherapy -- Periodicals; 616.99406105
• DOI: 10.1136/jitc-2020-002140
• Languages: English
• ISSNs: 2051-1426

Abstract

Abstract : Background: Cancer immunotherapy with monoclonal antibodies and chimeric antigen receptor (CAR) T cell therapies can benefit from selection of new targets with high levels of tumor specificity and from early assessments of efficacy and safety to derisk potential therapies. Methods: Employing mass spectrometry, bioinformatics, immuno-mass spectrometry and CRISPR/Cas9 we identified the target of the tumor-specific SF-25 antibody. We engineered IgE and CAR T cell immunotherapies derived from the SF-25 clone and evaluated potential for cancer therapy. Results: We identified the target of the SF-25 clone as the tumor-associated antigen SLC3A2, a cell surface protein with key roles in cancer metabolism. We generated IgE monoclonal antibody, and CAR T cell immunotherapies each recognizing SLC3A2. In concordance with preclinical and, more recently, clinical findings with the first-in-class IgE antibody MOv18 (recognizing the tumor-associated antigen Folate Receptor alpha), SF-25 IgE potentiated Fc-mediated effector functions against cancer cells in vitro and restricted human tumor xenograft growth in mice engrafted with human effector cells. The antibody did not trigger basophil activation in cancer patient blood ex vivo, suggesting failure to induce type I hypersensitivity, and supporting safe therapeutic administration. SLC3A2-specific CAR T cells demonstrated cytotoxicity against tumor cells, stimulated interferon-γ and interleukin-2 production in vitro. In vivo SLC3A2-specific CAR T cells significantly increased overall survival and reduced growth of subcutaneous PC3-LN3-luciferase xenografts. No weight loss, manifestations of cytokine release syndrome or graft-versus-host disease, were detected. Conclusions: These findings identify efficacious and potentially safe tumor-targeting of SLC3A2 with novel immune-activating antibody and genetically modified cell therapies.